Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV

Exclusion Criteria

• •Subjects presenting with any of the following will not be included in the study:
• •* Subjects to whom Eraxis IV is prescribed for other diseases than invasive candidiasis in adult patients.
• •* Subjects less than 18 ages should be excluded in this study since safety and effectiveness in pediatric patients have not been established yet.
• •* Hypersensitivity to the active substance, or to any of the excipients.
• •* Hypersensitivity to other medicinal products of the echinocandin class (e.g. caspofungin).
• •Subjects presenting with any of the following will not be included in the study:
• •Subjects to whom Eraxis IV was prescribed for other diseases than candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) (in case where the starting date of Eraxis IV administration is prior to 10 Mar 2015) or invasive candidiasis in adult patients (in case where the starting date of Eraxis IV administration is 10 Mar 2015 or after).
• •Subjects less than 18 ages should be excluded in this study since safety and effectiveness in pediatric patients have not been established yet.
• •Hypersensitivity to the active substance, or to any of the excipients.
• •Hypersensitivity to other medicinal products of the echinocandin class (e.g. caspofungin).
• •Subjects enrolled in the prospective phase study.